The measurement of natriuretic peptides has emerged as an important tool for the diagnosis and risk stratification of patients with heart failure, but the use of these markers for monitoring treatment remains under question. In this Review, Drs. O'Donoghue and Braunwald explore the evolving role of natriuretic peptides in the guidance of heart failure therapy and appraise data from clinical trials in this field.
- Michelle O'Donoghue
- Eugene Braunwald
